RESEARCH MONOGRAPH · KDC-MN-299

ABT-737

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

66/100

Navitoclax's not-orally-active research-only predecessor, a useful tool compound that never aspired to be more

ABT-737 is Abbott's original BH3 mimetic, the compound that proved the proof-of-concept and then got replaced by navitoclax (ABT-263) for clinical development because ABT-737 has effectively zero oral bioavailability. So it lives entirely in the research literature as a tool compound for studying BCL-2 family inhibition in vitro and in injection-based animal models.

Mechanistically ABT-737 is similar to navitoclax: it occupies the BH3 binding groove on BCL-2, BCL-XL, and BCL-W with high affinity, displaces pro-apoptotic BH3-only proteins, and triggers BAX/BAK-mediated mitochondrial outer membrane permeabilization in cells that depend on those antiapoptotic proteins for survival. The selectivity profile is genuinely tight for what it is, MCL-1 affinity is much lower which is the typical class-defining feature of the early BH3 mimetics.

The research utility is real. Most of the foundational senescent-cell-dependence-on-BCL-XL work was done with ABT-737 because it was the available tool when those studies started. The Roy/Campisi and Zhu/Tchkonia labs both used ABT-737 to validate BCL-XL dependence before navitoclax became available for the oral protocols. The literature on ABT-737 in senescence biology is genuinely substantial.

What we like: cleaner research-only positioning, no clinical baggage, and a well-characterized tool compound for in vitro and intraperitoneal-injection animal studies. The pharmacology mirrors navitoclax closely enough that the comparison studies are interpretable.

What we dont love is the formulation. ABT-737 is poorly water-soluble and requires DMSO or polyethoxylated castor oil vehicles for in vivo use, which limits the experimental designs you can run and adds vehicle-effect controls that are not trivial. Oral administration is essentially useless. So the practical research footprint is narrower than navitoclax's.

Sourcing is fine. ABT-737 is research-only material (no pharma-grade equivalent), and reliable suppliers ship reasonably consistent product. HPLC purity above 98 percent is standard, the molecule is stable, and the failure modes are limited to occasional residual solvent issues from the synthesis.

Honestly, ABT-737 versus navitoclax is mostly a question of administration route. For oral or chronic dosing, navitoclax. For mechanistic in vitro work or short-term injection models where you want the tool with the deeper literature, ABT-737 still earns its place.

Evidence: 60
Mechanism: 85
Reliability: 75
Safety: 55
Sourcing: 72
Value: 60
Signal: 65
Staying power: 55

Plain-language summary Intrigue 50 / 100

ABT-737 is the structural and pharmacological predecessor to navitoclax: same target profile (BCL-2, BCL-XL, BCL-W), same BH3-mimetic logic, same selective killing of senescent cells in animal models, but missing the modifications that made navitoclax orally bioavailable. So ABT-737 is a research-only compound, given by intraperitoneal injection in mouse studies and never developed for clinical use. It remains widely used in cancer biology and senolytic research as a comparator for newer BCL-2 family inhibitors and as a tool to probe BH3-mimetic biology in cell lines and primary cells. Of historical interest as the original molecule that established the senolytic potential of the BCL-2 family. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

BCL-2 family inhibitor (research)

The non-orally bioavailable predecessor of navitoclax; a BH3-mimetic research compound for BCL-2/BCL-XL inhibition studies.

Abstract

ABT-737 (CAS 852808-04-9; molecular formula C42H45ClN6O5S2; molecular weight 813.43) is a BH3-mimetic BCL-2/BCL-XL/BCL-W inhibitor developed at Abbott. The compound is the structural and pharmacological predecessor to navitoclax; navitoclax was developed by modifications introducing oral bioavailability while preserving the binding profile. Mechanism is identical to navitoclax: high-affinity binding to the BH3 groove of BCL-2 family anti-apoptotic proteins, releasing BAX and BAK to trigger mitochondrial apoptosis. The compound is not orally bioavailable and is administered intraperitoneally in animal studies. Senolytic activity has been demonstrated in multiple mouse models of senescence-associated disease. Used in academic research as a reference BH3 mimetic where oral delivery is unnecessary.

Mechanism of action

BH3-mimetic BCL-2 family inhibitor (BCL-2, BCL-XL, BCL-W). Same target profile as navitoclax. Not orally bioavailable.

Reported research dose ranges

Mouse IP studies 25 to 100 mg/kg.

References

Oltersdorf T, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005.
Yosef R, et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat Commun 2016.
Zhu Y, et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging 2017.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-299

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

ABT-737

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs